Overview
CSL Limited is an Australian multinational that operates primarily in the biotechnology industry, focusing on the development, manufacture, and marketing of therapies and vaccines. This includes products related to immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. Established in 1916 as the Commonwealth Serum Laboratories, CSL has evolved into a global healthcare leader. It undertakes significant projects, such as the production of flu vaccines and life-saving plasma-derived therapies. A critical area of expansion has been its Seqirus segment, which is notably the world’s second-largest influenza vaccine provider. CSL's strategic actions include significant investments in research and development to foster innovation while also undertaking acquisitions, such as the recent purchase of Vifor Pharma, enhancing its portfolio and global reach in specialty pharmaceuticals and iron deficiency treatments.
Basic Stats
The share price of CSL Limited - Depositary Receipt (Common Stock) as of June 10, 2024 is $95.07 / share.
The Factor Analysis chart (below right) shows a view of CSL Limited - Depositary Receipt (Common Stock) from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 484.21 MM |
| Earnings Date | |
| EPS (TTM) | 6.20 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-09-10 |
| Borrow Rate | 9.48 |
| Short Shares Avail. | 0.00 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.22 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.08 |
| ROE | 0.15 |
| ROIC | 0.09 |
| CROIC | 0.02 |
| OCROIC | 0.11 |
| Implied Volatility | |
| Put/Call OI Ratio |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for CSL Limited - Depositary Receipt (Common Stock) is $93.57. The forecasts range from a low of $73.66 to a high of $106.02. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for CSL Limited - Depositary Receipt (Common Stock). An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-12-23 | WILSONS | Overweight | Overweight | Maintains |
| 2023-10-12 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2023-08-31 | WILSONS | Overweight | Overweight | Maintains |
| 2023-08-30 | WILSONS | Overweight | Overweight | Maintains |
| 2023-08-16 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2023-08-15 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2023-06-09 | CREDIT SUISSE - AUSTRALIA | Outperform | Outperform | Maintains |
| 2023-06-08 | CREDIT SUISSE - AUSTRALIA | Outperform | Outperform | Maintains |
| 2023-06-07 | WILSONS | Overweight | Overweight | Maintains |
| 2023-06-06 | WILSONS | Overweight | Overweight | Maintains |
| 2023-06-06 | MACQUARIE RESEARCH | Neutral | Outperform | Upgrade |
| 2023-06-05 | MACQUARIE RESEARCH | Neutral | Outperform | Upgrade |
| 2023-04-15 | WILSONS | Overweight | Overweight | Maintains |
| 2023-03-29 | CREDIT SUISSE - AUSTRALIA | Neutral | Outperform | Upgrade |
| 2023-03-28 | CREDIT SUISSE - AUSTRALIA | Neutral | Outperform | Upgrade |
| 2023-02-15 | MACQUARIE RESEARCH | Neutral | Outperform | Upgrade |
| 2022-10-17 | CREDIT SUISSE - AUSTRALIA | Neutral | Neutral | Maintains |
| 2022-10-16 | CREDIT SUISSE - AUSTRALIA | Neutral | Neutral | Maintains |
| 2022-08-19 | BARCLAY PEARCE CAPITAL | Hold | Hold | Maintains |
| 2022-08-18 | BARCLAY PEARCE CAPITAL | Hold | Hold | Maintains |
| 2021-12-09 | CREDIT SUISSE - AUSTRALIA | Outperform | Neutral | Downgrade |
| 2021-12-08 | CREDIT SUISSE - AUSTRALIA | Outperform | Neutral | Downgrade |
| 2021-11-08 | MACQUARIE RESEARCH | Outperform | Neutral | Downgrade |
| 2021-11-07 | MACQUARIE RESEARCH | Outperform | Neutral | Downgrade |
| 2021-05-24 | MACQUARIE RESEARCH | Neutral | Outperform | Upgrade |
| 2021-05-23 | MACQUARIE RESEARCH | Neutral | Outperform | Upgrade |
| 2021-05-04 | CREDIT SUISSE - AUSTRALIA | Outperform | Outperform | Maintains |
| 2021-05-03 | CREDIT SUISSE - AUSTRALIA | Outperform | Outperform | Maintains |
| 2021-04-18 | MACQUARIE RESEARCH | Neutral | Neutral | Maintains |
| 2021-04-17 | MACQUARIE RESEARCH | Neutral | Neutral | Maintains |
| 2024-07-11 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2024-02-18 | MAQRO CAPITAL PTY LTD | Underperform | Underperform | Maintains |
| 2024-02-11 | WILSONS | Overweight | Overweight | Maintains |
| 2023-12-22 | WILSONS | Overweight | Overweight | Maintains |
| 2023-10-11 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2025-04-07 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2025-03-23 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2025-03-16 | JEFFERIES | Buy | Buy | Maintains |
| 2025-01-06 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2024-12-04 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2024-09-02 | E&P | Neutral | Neutral | Maintains |
| 2025-07-16 | JEFFERIES | Buy | Buy | Maintains |
| 2025-07-16 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2025-07-09 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
